marketshareAI

GENinCode

GENIHealthcare
1.5500GBX
-3.13%
Market Cap
4.45M
Volume
165
0% of avg
P/E Ratio
-0.01
EPS (TTM)
-2
Beta
0.6
Day Range
0.0000p - 0.0000p
52 Week Range
0.0000p1.5500p9.7600p
1.5500p

Upcoming Events

Preliminary Results
GENinCode to provide further update on FDA De Novo submission
High Impact Event
GENI
NEUTRAL

GENinCode Provides Update on FDA De Novo Submission

The genetics company provides an update on its FDA submission, indicating ongoing discussions to address outstanding elements identified by the regulator.

GENI
NEUTRAL

GENinCode Grants Share Options to Directors

The genetics company has granted share options to its directors and employees as part of an incentive scheme.

GENI
NEUTRAL

GENinCode Plc Announces Change in Major Shareholding

The diagnostics company announces a decrease in shareholding by a major investor, but the news appears to have no material impact on the business.

GENI
NEUTRAL

GENinCode Plc Announces Change in Major Shareholding

The diagnostics company has announced a change in major shareholding, with no further details provided.

GENI
NEUTRAL

GENinCode Plc Announces Change in Major Shareholding

The diagnostics company announces a change in major shareholding, with Dowgate Group Limited acquiring a 7.04% stake.

GENI
BAD

GENinCode Raises £4.1m in Discounted Retail Offer

The genetics company has raised £4.1 million through a discounted Retail Offer, suggesting low investor appetite and potential underlying challenges.

GENI
NEUTRAL

GENinCode Raises £4M in Discounted Placing

The healthcare diagnostics company has raised £4 million through a discounted share placing, providing capital but signaling potential ongoing challenges.

GENI
NEUTRAL

GENinCode Announces Retail Offer as Part of Broader Fundraising

The genetics company announces a retail offer of new shares as part of a broader fundraising, with proceeds to be used for growth and expansion.

GENI
NEUTRAL

GENinCode Plc Raises £4.0 Million Through Placing and Subscription

The genetics company is raising £4.0 million through a placing and subscription to fund its regulatory and commercialization plans in the US, UK, and Europe.

GENI
GOOD

GENinCode Expands CARDIO inCode Adoption in US and Spain

The healthcare company announces key milestones for its cardiovascular disease prevention technology, including US reimbursement and Spanish regional launch, positioning it for growth.